Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of TV-1380 in healthy male volunteers
NL-OMON34473Phase 1Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2010
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, double-blind trial of TV-1380 in cocaine use disorder (CUD) and cocaine intoxication, sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Ex vivo cocaine hydrolysis, Serum TV-1380 concentrations and 7 more. Started Aug 2010; status: active, not recruiting.
02
Drugs
TV-1380
03
Conditions
cocaine use disorder (CUD)cocaine intoxication
Beyond the preview
Go deeper on NL-OMON34473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34473.